Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20312519 | 0.92 | ALK (0.45) | MAPK10MAPK9ALKINSRIGF1R | |
| SCHEMBL690645 | 0.85 | MAPK10 (0.49) | MAPK10MAPK9ALKMAPK1MAPK3 | |
| SCHEMBL1293075 | 0.83 | ALK (0.49) | MAPK10MAPK9ALKMAPK1INSR | |
| SCHEMBL691560 | 0.83 | MAPK1 (0.48) | MAPK10MAPK9MAPK1MAPK3PTK2 | |
| SCHEMBL22174599 | 0.80 | MAPK10 (0.41) | MAPK10MAPK9MAPK1MAPK3PTK2 | |
| SCHEMBL691660 | 0.80 | MAPK3 (0.60) | MAPK10MAPK9MAPK1MAPK3PTK2 | |
| SCHEMBL691689 | 0.78 | MAPK1 (0.47) | MAPK10MAPK9MAPK1MAPK3JAK2 | |
| SCHEMBL20312520 | 0.77 | ALK (0.45) | MAPK10MAPK9ALKMAPK1MAPK3 | |
| SCHEMBL12413670 | 0.77 | MAPK10 (0.56) | MAPK10MAPK9ALKMAPK1MAPK3 | |
| SCHEMBL1559161 | 0.73 | MAPK9 (0.51) | MAPK10MAPK9ALKMAPK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-06-05 | — | — | US | claimed |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2014-04-17 | — | — | US | claimed |
| EP-2421537-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2012-02-29 | — | — | EP | claimed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | claimed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | claimed |
| WO-2010062578-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | claimed |
| US-11564927-B2 | Therapeutic compositions, combinations, and methods of use | VERASTEM, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-04-28 | — | — | US | disclosed |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-02-04 | — | — | US | disclosed |
| US-20200330471-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | RGCM SA LLC, AS PURCHASER AGENT | 2020-10-22 | — | — | US | disclosed |
| WO-2020135442-A1 | FAK INHIBITOR AND DRUG COMBINATION THEREOF | 成都海创药业有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-20180177788-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | RGCM SA LLC, AS PURCHASER AGENT | 2018-06-28 | — | — | US | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-08-25 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564927-B2 | Therapeutic compositions, combinations, and methods of use | PTK2, CD274, PDCD1LG2 | MAPK10 804/4885MAPK9 1136/4885ALK 1132/4885 |
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK9 386/4885ALK 665/4885 |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | CD274, PDCD1, PDCD10 | MAPK10 1805/4885MAPK9 3263/4885ALK 4801/4885 |
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK9 386/4885ALK 665/4885 |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | CD274, PDCD1, PTK2 | MAPK10 227/4885MAPK9 266/4885ALK 595/4885 |
| US-20110207743-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK9 386/4885ALK 665/4885 |
| US-20200330471-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CD274, PDCD1LG2 | MAPK10 804/4885MAPK9 1136/4885ALK 1132/4885 |
| US-20140107131-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK9 386/4885ALK 665/4885 |
| US-20140155410-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK10 656/4885MAPK9 386/4885ALK 665/4885 |
| US-20180177788-A1 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | PTK2, CD274, PDCD1LG2 | MAPK10 804/4885MAPK9 1136/4885ALK 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.